ReviewJournal of thrombosis and thrombolysis2010
New oral anticoagulants: a practical guide for clinicians.
Review in Journal of thrombosis and thrombolysis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 51 citations in OpenAlex.
- Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.Cardiology research and practice · 2012Article
- Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2011Article
- Direct thrombin inhibitors.British journal of clinical pharmacology · 2011Review
- Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.Journal of thrombosis and thrombolysis · 2011Review
- New options in anticoagulation for the prevention of venous thromboembolism and stroke.P & T : a peer-reviewed journal for formulary management · 2011Article
- Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.The journal of Tehran Heart Center · 2010Article
- Beyond warfarin: The advent of new oral anticoagulants.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for an oral anticoagulant with acceptable efficacy and safety in the treatment and prevention of venous and arterial thromboembolism, but with practical advantages over warfarin, has been a focus of drug development for many years. Three oral agents, dabigatran, rivaroxaban, and apixaban, are nearing approval in the US. Their use in practice will be guided by the clinical trials available, as well as their pharmacokinetic and pharmacodynamic properties. Practitioners need to be fully aware of these characteristics in order to use these agents appropriately in clinical practice. This review compares the results of the phase 3 trials investigating these agents in the prevention of venous thromboembolism in patients undergoing orthopedic surgery, examines the reporting of bleeding complications in the trials, and highlights various practical considerations regarding their use in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.